Instalab

Total Fecal Fat Test Stool

See whether your gut is actually absorbing the fat from your food, or quietly losing it.

Should you take a Total Fecal Fat test?

This test is most useful if any of these apply to you.

Living With Pancreatic Disease
If you have chronic pancreatitis, cystic fibrosis, or have had pancreas surgery, this confirms whether your enzyme therapy is restoring absorption.
Losing Weight You Cannot Explain
If you are dropping pounds without trying or have nutrient deficiencies, this can show whether your gut is silently failing to absorb dietary fat.
Dealing With Chronic Diarrhea
If loose, greasy, or hard-to-flush stools have become a pattern, this can distinguish true fat malabsorption from other causes of diarrhea.
Recovering From Bowel Surgery
If you have had part of your small intestine removed or have bariatric surgery in your past, this checks whether absorption is keeping up with your needs.

About Total Fecal Fat

If you have been losing weight without trying, dealing with greasy or hard-to-flush stools, or struggling with chronic diarrhea that no one can explain, the fat in your stool may hold the answer. This test counts how much dietary fat your gut fails to absorb, which is the most direct way to confirm whether your digestive system is breaking food down properly.

The number reveals whether your pancreas, bile system, and intestines are doing the job of pulling fat out of what you eat. When that machinery falters, fat slips through and shows up in stool, often years before nutrient deficiencies or weight loss become obvious.

What This Test Actually Measures

Total fecal fat is the combined weight of all fat lipids in your stool, including triglycerides (the main form of fat in food) and free fatty acids (fat that has been partially broken down). It is not one molecule but the sum of every fat type your gut failed to absorb.

Almost all of the fat measured comes from your diet, not from your body. Used carefully, the result lets a clinician calculate the coefficient of fat absorption, the percentage of dietary fat your gut actually pulled in. That percentage is considered the gold-standard measure of how well your digestive system handles fat.

Pancreatic Insufficiency

The most common reason for elevated fecal fat is exocrine pancreatic insufficiency (EPI), a condition where the pancreas does not make enough of the enzymes needed to digest fat. In chronic pancreatitis, the median fecal fat output is about 12 grams per day, compared with 5 grams per day in people without pancreatic disease and in healthy controls.

Pancreatic enzyme replacement therapy (PERT), the standard treatment, reduces fecal fat and improves the percentage of fat absorbed. This is why fecal fat is used both to diagnose pancreatic insufficiency and to confirm that treatment is actually working.

Cystic Fibrosis

In cystic fibrosis, fat malabsorption is nearly universal. Even with PERT, median fecal fat is around 8 grams per day with a fat absorption coefficient of about 90 percent. Higher fecal fat tracks with lower stool pH (more acidic stool), which interferes with how well the pancreatic enzymes work in the gut.

Irritable Bowel Syndrome

In irritable bowel syndrome, fecal fat is one of the strongest predictors of whether someone has clinically significant diarrhea or constipation. Levels above 14 grams per day in someone with diarrhea suggest something other than functional IBS is driving symptoms, and warrant a workup for malabsorption.

Kidney Stones and Ileal Disease

In people with disease or surgical removal of the lower small intestine (the ileum), elevated fecal fat is linked to a higher risk of calcium oxalate kidney stones. Unabsorbed fat binds calcium in the gut, leaving more oxalate free to be absorbed and end up in urine. Lowering dietary fat in this population reduces both fecal fat and urinary oxalate.

Reference Ranges

The cutpoints below come from research using standardized stool collections (typically 48 to 72 hours) on a controlled fat intake of about 100 grams per day. They are diagnostic thresholds for steatorrhea, not preventive or longevity targets, and a small number of healthy people may exceed them transiently. Your lab may use slightly different units or thresholds depending on its method.

TierRange (grams per day)What It Suggests
NormalLess than 7Adequate fat absorption in most adults
Borderline7 to 14Mild or mixed malabsorption; needs clinical context
ElevatedGreater than 14Significant malabsorption, often pancreatic in origin

Source: thresholds drawn from research on chronic pancreatitis and steatorrhea diagnosis. Compare your results within the same lab over time for the most meaningful trend, since assays vary.

Why a Single Reading Can Fool You

This test is unusually sensitive to what you eat in the days before collection. Fecal fat output rises with dietary fat intake, so a result is most useful when interpreted relative to a known fat intake (often standardized at 100 grams per day for several days before collection). A low-fat diet during collection can mask real malabsorption; an unusually high-fat diet can produce a borderline-looking result in a healthy gut.

  • Diarrhea itself: mild diarrhea from any cause can push fecal fat up to about 14 grams per day without true fat malabsorption, so mildly elevated results in someone with active diarrhea may not point to a primary digestive defect.
  • High-calcium dairy intake: a randomized crossover trial showed that switching to a high-calcium dairy diet roughly doubled fecal fat (from about 5 to 11 grams per day) in healthy adults, because calcium binds fat into unabsorbable soaps in the gut.
  • Flaxseed and other viscous fibers: these increase fecal fat by trapping fat in stool, not by causing disease.
  • Stool water content: very loose, watery stool can dilute fat measurements and lead to falsely low concentrations even when total daily output is high.

Drug-Induced Changes

Orlistat, a weight-loss medication that blocks pancreatic lipase, deliberately increases fecal fat in people on a controlled fat diet. This is the drug working as designed, not a sign of disease. If you are taking orlistat, fecal fat results will look like severe malabsorption even though your gut is healthy. Stop the medication for at least a week before testing if you want to assess your underlying digestion.

Tracking Your Trend

A single fecal fat number is hard to interpret without context. The most reliable approach is a baseline reading on a standardized fat intake, then a follow-up after any intervention that should change absorption, such as starting pancreatic enzyme therapy, treating bile acid malabsorption, or modifying diet.

For people on PERT, retesting at 3 to 6 months after starting therapy or adjusting doses confirms whether the dose is high enough to actually correct malabsorption. Symptoms alone (greasy stools, bloating, weight stability) are not reliable signals that absorption has normalized. For ongoing monitoring of chronic conditions like cystic fibrosis or chronic pancreatitis, annual testing is reasonable, with more frequent checks if symptoms or weight shift.

What to Do With an Abnormal Result

An elevated fecal fat result is not a diagnosis on its own. It tells you fat absorption is impaired, but not why. The next step is to figure out which part of the system is failing: the pancreas, the bile flow, or the intestinal lining itself.

  • Fecal elastase-1: a simpler stool test that screens specifically for pancreatic enzyme output. A low elastase plus high fecal fat strongly points to pancreatic insufficiency.
  • Celiac panel (tTG IgA and total IgA): rules out celiac disease, a common cause of intestinal malabsorption that can produce high fecal fat.
  • Vitamin and mineral panel: fat-soluble vitamins (A, D, E, K), B12, iron, and magnesium are commonly low in chronic malabsorption and confirm that the elevated fecal fat is having clinical consequences.
  • Imaging or specialist referral: unexplained malabsorption with normal celiac and elastase results often needs a gastroenterologist to consider chronic pancreatitis on imaging, bile acid issues, or small intestinal causes.

If your result is borderline (7 to 14 grams per day) and you have no symptoms, the most useful next step is usually to repeat the test on a more carefully standardized diet before pursuing a full workup.

What Moves This Biomarker

Evidence-backed interventions that affect your Total Fecal Fat level

Decrease
Pancreatic enzyme replacement therapy (PERT)
PERT is the standard-of-care treatment for pancreatic exocrine insufficiency. In chronic pancreatitis with insufficiency, PERT significantly reduces fecal fat and energy loss, and improves the coefficient of fat absorption. A meta-analysis of clinical trials found PERT effectively addresses pancreatic insufficiency and the malnutrition it causes, with higher doses, enteric-coated formulations, and dosing with food producing the best results. If your fecal fat is high because of pancreatic insufficiency, PERT brings absorption back toward normal and prevents weight loss and vitamin deficiencies.
MedicationStrong Evidence
Increase
Orlistat (weight-loss lipase blocker)
Orlistat blocks the pancreatic enzyme that breaks down fat, so fat passes through undigested. In a randomized trial in healthy volunteers on a controlled fat diet, orlistat substantially increased fecal fat excretion within one week. This is the drug working as intended for weight loss, but it produces results that mimic severe malabsorption on a fecal fat test. If you are taking orlistat, this is a measurement artifact rather than evidence of digestive disease, and you should stop the drug before testing if you want to assess your true absorption.
MedicationStrong Evidence
Increase
High-calcium dairy diet
In a randomized crossover trial of healthy adults, switching to a high-calcium dairy diet roughly doubled fecal fat excretion (from about 5 to 11 g/day). Calcium binds with fat in the gut to form unabsorbable soaps, increasing fat lost in stool without indicating any underlying digestive problem. The mechanism is mechanical, not pathological, and the modest extra fat loss has been studied as a potential contributor to weight management.
DietStrong Evidence
Decrease
Low-fat diet for ileal disease or short bowel
In people with disease or surgical removal of the lower small intestine, reducing dietary fat lowers both fecal fatty acid output and urinary oxalate, and reduces the risk of calcium oxalate kidney stones. A separate study in small bowel disease found a low-fat diet reduced chronic diarrhea symptoms, with the largest improvement in those with intact gallbladder function. This is a targeted intervention for people with confirmed ileal dysfunction, not a general recommendation.
DietStrong Evidence
Increase
Flaxseed dietary fibers
In a randomized trial of adults, flaxseed fibers increased fecal fat excretion and the energy lost in stool, with the magnitude depending on how the flaxseed was processed and the food matrix it was added to. Like high-calcium dairy, this works by trapping fat in stool rather than by impairing digestion, and it can mildly lower blood cholesterol as a side benefit.
DietModerate Evidence
Decrease
Medium-chain triglyceride (MCT) substitution
Medium-chain triglycerides are absorbed without needing pancreatic enzymes or bile acids, so substituting them for regular dietary fat improves fat absorption in malabsorption states. In a randomized trial of HIV patients with chronic diarrhea, an MCT-based diet reduced both diarrhea and fat malabsorption regardless of cause. A scoping review in children with cholestatic liver disease found MCT supplementation may improve fat absorption and growth, though high MCT percentages risk essential fatty acid deficiency.
DietModerate Evidence

Frequently Asked Questions

References

20 studies
  1. Erchinger F, Engjom T, Jurmy P, Tjora E, Gilja O, Dimcevski GPLoS ONE2017
  2. De La Iglesia D, Agudo-castillo B, Galego-fernández M, Rama-fernández a, Domínguez-muñoz JUnited European Gastroenterology Journal2025
  3. Iglesia-garcía D, Huang W, Szatmary P, Bastón-rey I, Gonzalez-lopez J, Prada-ramallal G, Mukherjee R, Nunes QM, Domínguez-muñoz J, Sutton RGut2016
  4. Calvo-lerma J, Boon M, Colombo C, De Koning B, Asseiceira I, Garriga MJournal of Cystic Fibrosis2020
  5. Walker BE, Kelleher J, Davies T, Smith C, Losowsky MGastroenterology1973